alpelisib
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA-Related Overgrowth Spectrum (PROS)
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)
Trial Timeline
— → —
NCT ID
NCT04085653About alpelisib
alpelisib is a pre-clinical stage product being developed by Novartis for PIK3CA-Related Overgrowth Spectrum (PROS). The current trial status is active. This product is registered under clinical trial identifier NCT04085653. Target conditions include PIK3CA-Related Overgrowth Spectrum (PROS).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04085653 | Pre-clinical | Active |
| NCT03706573 | Pre-clinical | Completed |
| NCT06997588 | Phase 2 | Recruiting |
| NCT04980833 | Phase 2 | Active |
| NCT02624557 | Phase 1 | Completed |
Competing Products
6 competing products in PIK3CA-Related Overgrowth Spectrum (PROS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib + Placebo | Novartis | Phase 2 | 52 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 47 |